Olema Oncology announced it has strengthened its executive team with the appointment of Shane Kovacs as Chief Operating Officer, Kinney Horn as Chief Business Officer, and John B. Moriarty as Executive Vice President, Chief Legal Officer. In addition, Pamela Klein will serve as company's Chief Medical Officer, and David Myles has been promoted to Chief Development Officer. Kovacs will lead company's financial strategy, accounting, information technology and human resources functions. Horn will lead the business and corporate development function, including strategy and partnerships, and will play a key role in business operations. Moriarty will serve as company's chief legal officer, leading all legal, regulatory, governance and compliance initiatives. Klein will guide company's clinical development efforts, including clinical strategy, medical affairs, clinical operations, clinical pharmacokinetics, biometrics, regulatory affairs and quality. Myles will continue to lead the company's preclinical development and CMC operations and oversee ongoing discovery chemistry efforts. Shane Kovacs has more than 20 years of biotechnology operating experience, including a strong background in capital markets and M&A. Prior to joining Olema, he was Chief Business and Financial Officer of BlueRock Therapeutics, LP. Kinney Horn has 20 years of experience in life science finance, leadership and biopharmaceutical business development roles. During his 16-year career at Genentech, he participated in a number of transactions, including the acquisition of Seragon Pharmaceuticals and key product technology collaborations with Xencor, Affimed, Hanmi, Immunocore, Seattle Genetics, Vernalis, NCM USA, Kasia and Tercica. John B. Moriarty has more than 25 years of legal and biotech experience across leading global biotech companies. Most recently, he was Executive Vice President and General Counsel for Portola Pharmaceuticals, Inc. Pamela Klein is a medical oncologist and seasoned biotechnology executive and advisor with 20 years of experience in drug development. She has served as Chief Medical Officer/Acting Chief Medical Officer for multiple successful biotech companies including Intellikine (acquired by Takeda) and Syndax Pharmaceuticals. David Myles has more than 20 years of experience in oncology-focused drug discovery and development. Since joining Olema shortly after its inception as Executive Vice President, Drug Discovery and Development, he has led Olema's discovery chemistry, CMC and IND-enabling efforts. Prior to joining Olema, he served as Executive Director at Kosan Biosciences where he was program leader on one of its leading oncology initiatives and led discovery and development chemistry programs, which led to the identification and advancement of clinical candidates in oncology and other indications.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
OLEMA PHARMACEUTICALS, INC. 
